Archive

Evaluation of the World Health Organization-HEARTS hypertension control package in Bangladesh: a quasi-experimental trial
Evaluation of the World Health Organization-HEARTS hypertension control package in Bangladesh: a quasi-experimental trial The World Health Organization (WHO) promotes the HEARTS technical package for improving hypertension control worldwide, but its effectiveness has not been rigorously evaluated.


Common Eye Disorder May Be Linked to Maternal Hypertension
Common Eye Disorder May Be Linked to Maternal Hypertension Children whose mothers have a hypertensive disorder in pregnancy (HDP) may have an increased risk for strabismus, including exophoria and intermittent exotropia, new research shows. Preeclampsia and poorly controlled blood pressure may confer the greatest risk.


PET Imaging Finds Vulnerable Plaques That Cause MI
PET Imaging Finds Vulnerable Plaques That Cause MI A new technique that can locate vulnerable coronary plaques at risk of rupturing and causing a myocardial infarction (MI) could help identify patients at high cardiovascular risk who might need more intensive treatment.


New Insight Into CVD, Stroke Risk in Migraine
New Insight Into CVD, Stroke Risk in Migraine Researchers are unraveling the complex relationship between cardiovascular (CV)- and stroke-related outcomes in migraine with, and without, aura.


How to Get Published in a Specialized Journal
How to Get Published in a Specialized Journal Every month, hundreds of manuscripts land in the inboxes of biomedical journals. For example, researchers submitted more than 2200 articles to JAMA Cardiology in 2023. Only 6% of all original research papers were accepted.


Roche Blood Test for Lp(a) Designated Breakthrough Device
Roche Blood Test for Lp(a) Designated Breakthrough Device A blood test that measures lipoprotein(a) [Lp(a)] has received breakthrough device designation from the US Food and Drug Administration. The Tina-quant Lp(a) RxDx assay, developed by Roche in partnership with Amgen, is designed to identify adults with elevated Lp(a) levels who may benefit from lipid-lowering therapies currently in development.


New TAVI Platform Adds More Valve Sizes to Choose From
New TAVI Platform Adds More Valve Sizes to Choose From Intermediate valve sizes are at least as safe and effective as the standard sizes now available for transcatheter aortic valve implantation (TAVI), according to an international randomized trial.


World Red Cross Day and Red Crescent Day
World Red Cross Day and Red Crescent Day World Red Cross Day and Red Crescent Day is celebrated on 8 May every year. This date is the birth anniversary of Henry Dunant, who was born on 8 May 1828 at Geneva, Switzerland, and died on 30 October 1910 at Heiden, Switzerland. He was the founder of (ICRC) International Committee of the Red Cross and the recipient of the first Nobel Peace Prize in 1901.


Lower CVD Risk With Stable DMARD Therapy in Seropositive Rheumatoid Arthritis
Lower CVD Risk With Stable DMARD Therapy in Seropositive Rheumatoid Arthritis The risk for cardiovascular diseases (CVDs) is lower in patients with seropositive rheumatoid arthritis (RA) who remain on stable disease-modifying antirheumatic drug (DMARD) therapy than in those whose treatment regimen is not stable.


Novel PCSK9 Inhibitor Reduced LDL by 50%
Novel PCSK9 Inhibitor Reduced LDL by 50% Lerodalcibep, a novel, third-generation proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, reduced low-density lipoprotein cholesterol (LDL-C) by more than 50% after 1 year in patients with or at a high risk for cardiovascular disease (CVD), new phase 3 results showed.